BRPI0917492A2 - Processos para preparação de metil éster de ácido 4-oxo-octa-hidro-indol-1-carboxílio e derivados dos mesmos - Google Patents

Processos para preparação de metil éster de ácido 4-oxo-octa-hidro-indol-1-carboxílio e derivados dos mesmos

Info

Publication number
BRPI0917492A2
BRPI0917492A2 BRPI0917492-3A BRPI0917492A BRPI0917492A2 BR PI0917492 A2 BRPI0917492 A2 BR PI0917492A2 BR PI0917492 A BRPI0917492 A BR PI0917492A BR PI0917492 A2 BRPI0917492 A2 BR PI0917492A2
Authority
BR
Brazil
Prior art keywords
octahydro
indol
oxo
derivatives
preparing
Prior art date
Application number
BRPI0917492-3A
Other languages
English (en)
Inventor
Ernst Kuesters
Murat Acemoglu
Philipp Lustenberger
Gottfried Sedelmeier
Beat Schmidt
Gerhard Penn
Original Assignee
Novartis Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=41278189&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=BRPI0917492(A2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Novartis Ag filed Critical Novartis Ag
Publication of BRPI0917492A2 publication Critical patent/BRPI0917492A2/pt
Publication of BRPI0917492A8 publication Critical patent/BRPI0917492A8/pt

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D209/00Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/02Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
    • C07D209/04Indoles; Hydrogenated indoles
    • C07D209/08Indoles; Hydrogenated indoles with only hydrogen atoms or radicals containing only hydrogen and carbon atoms, directly attached to carbon atoms of the hetero ring
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D209/00Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/02Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
    • C07D209/04Indoles; Hydrogenated indoles
    • C07D209/10Indoles; Hydrogenated indoles with substituted hydrocarbon radicals attached to carbon atoms of the hetero ring
    • C07D209/18Radicals substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C07D209/26Radicals substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals with an acyl radical attached to the ring nitrogen atom
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404Indoles, e.g. pindolol
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07CACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C271/00Derivatives of carbamic acids, i.e. compounds containing any of the groups, the nitrogen atom not being part of nitro or nitroso groups
    • C07C271/06Esters of carbamic acids
    • C07C271/08Esters of carbamic acids having oxygen atoms of carbamate groups bound to acyclic carbon atoms
    • C07C271/24Esters of carbamic acids having oxygen atoms of carbamate groups bound to acyclic carbon atoms with the nitrogen atom of at least one of the carbamate groups bound to a carbon atom of a ring other than a six-membered aromatic ring
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D203/00Heterocyclic compounds containing three-membered rings with one nitrogen atom as the only ring hetero atom
    • C07D203/04Heterocyclic compounds containing three-membered rings with one nitrogen atom as the only ring hetero atom not condensed with other rings
    • C07D203/06Heterocyclic compounds containing three-membered rings with one nitrogen atom as the only ring hetero atom not condensed with other rings having no double bonds between ring members or between ring members and non-ring members
    • C07D203/08Heterocyclic compounds containing three-membered rings with one nitrogen atom as the only ring hetero atom not condensed with other rings having no double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to the ring nitrogen atom
    • C07D203/14Heterocyclic compounds containing three-membered rings with one nitrogen atom as the only ring hetero atom not condensed with other rings having no double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to the ring nitrogen atom with carbocyclic rings directly attached to the ring nitrogen atom
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07CACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C2601/00Systems containing only non-condensed rings
    • C07C2601/12Systems containing only non-condensed rings with a six-membered ring
    • C07C2601/14The ring being saturated

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Indole Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
BRPI0917492A 2008-08-12 2009-08-10 processos para preparação de metil éster de ácido 4-oxo-octa-hidro-indol-1-carboxílico e derivados dos mesmos BRPI0917492A8 (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US8815608P 2008-08-12 2008-08-12
PCT/EP2009/060351 WO2010018154A1 (en) 2008-08-12 2009-08-10 Processes for the preparation of 4-oxo-octahydro-indole-1-carbocylic acid methyl ester and derivatives thereof

Publications (2)

Publication Number Publication Date
BRPI0917492A2 true BRPI0917492A2 (pt) 2015-08-04
BRPI0917492A8 BRPI0917492A8 (pt) 2016-07-05

Family

ID=41278189

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0917492A BRPI0917492A8 (pt) 2008-08-12 2009-08-10 processos para preparação de metil éster de ácido 4-oxo-octa-hidro-indol-1-carboxílico e derivados dos mesmos

Country Status (21)

Country Link
US (1) US8084487B2 (pt)
EP (1) EP2315748B1 (pt)
JP (1) JP5468608B2 (pt)
KR (1) KR101673634B1 (pt)
CN (1) CN102119151A (pt)
AU (1) AU2009281218B2 (pt)
BR (1) BRPI0917492A8 (pt)
CA (1) CA2732095C (pt)
CL (1) CL2011000296A1 (pt)
CO (1) CO6341608A2 (pt)
EC (1) ECSP11010883A (pt)
ES (1) ES2547269T3 (pt)
IL (1) IL210835A (pt)
MA (1) MA32618B1 (pt)
MX (1) MX2011001664A (pt)
MY (1) MY151183A (pt)
NZ (1) NZ590753A (pt)
PE (1) PE20110415A1 (pt)
RU (1) RU2513856C2 (pt)
WO (1) WO2010018154A1 (pt)
ZA (1) ZA201100558B (pt)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2655326A1 (en) * 2010-12-20 2013-10-30 Novartis AG 4- (hetero) aryl - ethynyl - octahydro - indole - 1 - carboxylic acid esters
EP2668159A1 (en) 2011-01-24 2013-12-04 Novartis AG 4-tolyl-ethynyl-octahydro-indole-1-ester derivatives
EP2650284A1 (en) 2012-04-10 2013-10-16 Merz Pharma GmbH & Co. KGaA Heterocyclic derivatives as metabotropic glutamate receptor modulators
GB201312800D0 (en) 2013-07-17 2013-08-28 Heptares Therapeutics Ltd mGlu5 modulators
CA3067688A1 (en) 2017-07-31 2019-02-07 Novartis Ag Use of mavoglurant in the reduction of alcohol use or in preventing relapse into alcohol use
EP3661500B1 (en) 2017-07-31 2026-01-07 Novartis AG Use of mavoglurant in the reduction of cocaine use or in preventing relapse into cocaine use
KR20210120011A (ko) * 2019-01-29 2021-10-06 노파르티스 아게 오피오이드 진통제 내약성을 치료하기 위한 mglur5 길항제의 용도
JP7620694B2 (ja) * 2020-07-17 2025-01-23 ノバルティス アーゲー オピオイド使用の低減用医薬品及びオピオイド禁断の促進用医薬品
IL303248A (en) 2020-12-11 2023-07-01 Novartis Ag Use of mglur5 antagonists for treating amphetamine addiction
AU2021404023A1 (en) 2020-12-14 2023-06-29 Novartis Ag Use of mglur5 antagonists for treating gambling disorder

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0128996D0 (en) * 2001-12-04 2002-01-23 Novartis Ag Organic compounds
GB0514296D0 (en) * 2005-07-12 2005-08-17 Novartis Ag Organic compounds
JP2010502664A (ja) * 2006-09-11 2010-01-28 ノバルティス アクチエンゲゼルシャフト 代謝型グルタミン酸受容体の調節剤としてのニコチン酸誘導体
AU2008309621A1 (en) * 2007-10-12 2009-04-16 Novartis Ag Metabotropic glutamate receptor modulators for the treatment of Parkinson's Disease
MX2010014222A (es) * 2008-06-30 2011-03-29 Novartis Ag Star Combinaciones que comprenden moduladores de mglur para el tratamiento de enfermedad de parkinson.

Also Published As

Publication number Publication date
PE20110415A1 (es) 2011-07-04
BRPI0917492A8 (pt) 2016-07-05
RU2513856C2 (ru) 2014-04-20
US8084487B2 (en) 2011-12-27
US20110144352A1 (en) 2011-06-16
CN102119151A (zh) 2011-07-06
NZ590753A (en) 2012-06-29
HK1155733A1 (en) 2012-05-25
EP2315748B1 (en) 2015-06-24
IL210835A (en) 2016-05-31
WO2010018154A1 (en) 2010-02-18
AU2009281218A1 (en) 2010-02-18
IL210835A0 (en) 2011-04-28
MA32618B1 (fr) 2011-09-01
CA2732095A1 (en) 2010-02-18
KR20110042222A (ko) 2011-04-25
EP2315748A1 (en) 2011-05-04
KR101673634B1 (ko) 2016-11-07
JP2011530566A (ja) 2011-12-22
ZA201100558B (en) 2011-10-26
CL2011000296A1 (es) 2011-11-04
CA2732095C (en) 2017-04-25
AU2009281218B2 (en) 2013-05-16
ES2547269T3 (es) 2015-10-05
CO6341608A2 (es) 2011-11-21
ECSP11010883A (es) 2011-04-29
MX2011001664A (es) 2011-03-25
RU2011108663A (ru) 2012-09-20
MY151183A (en) 2014-04-30
JP5468608B2 (ja) 2014-04-09

Similar Documents

Publication Publication Date Title
BRPI0917492A2 (pt) Processos para preparação de metil éster de ácido 4-oxo-octa-hidro-indol-1-carboxílio e derivados dos mesmos
LT3037089T (lt) Eikozapentaeno rūgšties etilo esteris skirtas hipertriglicidemijai gydydti
BRPI0909780A2 (pt) Composições e métodos para liberação de fármaco
BRPI0920927A2 (pt) derivados de azaquinolinona e usos dos mesmos
BRPI0912480A2 (pt) compostos de monoalquiltina de alta pureza e usos dos mesmos
BRPI0919447A2 (pt) derivados do ácido 1-amino-2-ciclobutiletilborônico
BRPI0915300A2 (pt) composto de éster boronato e composições farmaceuticas dos mesmos
BRPI0920804A2 (pt) método para preparar alquil ésteres de ácido graxo.
DK2231606T3 (da) Fremgangsmåder til fremstilling af cycloalkylcarboxamidopyridinbenzoesyrer
BRPI0909655A2 (pt) Processo para a preparação regioseletiva de derivados de ácido 1-alquil-3-haloalquil-pirazol-4carboxílico
BRPI0908906A2 (pt) compostos heterocíclicos e usos dos mesmos
PT2427212T (pt) Anticorpos anti-cd100 e métodos para utilização dos mesmos
BRPI1010024A2 (pt) derivados de aminopirrolidinona e uso dos mesmos
PT2456304E (pt) Métodos de modulação de ácidos de cadeia ramificada e utilização dos mesmos
DK2391349T3 (da) Farmaceutisk sammensætning omfattende 2-oco-1-pyrrolidin-derivater
BRPI1008752A2 (pt) compostos alquilamido e usos dos mesmos
EP2275414A4 (en) Cyclopentylacrylic acid amide derivative
BRPI0916360A2 (pt) processo para preparar derivados de ácido r-beta-amino fenilbutírico
BRPI0921654A2 (pt) formulação farmacêutica
BRPI0912428A2 (pt) formulação farmacêutica sólida de liberação retardada
BRPI0809615A2 (pt) misturas antioxidantes para ésteres metílicos de ácido graxo (biodiesel)
FI20085080A0 (fi) Tukielin kranaatin tukemiseksi ja menetelmä
BRPI0917562A2 (pt) composições farmacêuticas e métodos para estabilizar as mesmas
BRPI0912656A2 (pt) formulação farmacêutica sólida
BRPI0919200A2 (pt) derivado de aminoácido

Legal Events

Date Code Title Description
B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]
B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]

Free format text: EM VIRTUDE DO ARQUIVAMENTO PUBLICADO NA RPI 2474 DE 05-06-2018 E CONSIDERANDO AUSENCIA DE MANIFESTACAO DENTRO DOS PRAZOS LEGAIS, INFORMO QUE CABE SER MANTIDO O ARQUIVAMENTO DO PEDIDO DE PATENTE, CONFORME O DISPOSTO NO ARTIGO 12, DA RESOLUCAO 113/2013.